Crispene E 

Crispene E is a STAT3 inhibitor with an IC₅₀ of 10.27 μM against STAT3 dimerization. Crispene E exerts specific cytotoxicity against STAT3-dependent MDA-MB-231 breast cancer cells. Crispene E is applicable to research related to breast cancer^[1].

Crispene E (0-100 μM; 24 h) selectively reduces the viability of STAT3-dependent MDA-MB-231 breast cancer cells, with an IC₅₀ of 5.35 μM at 24 h, whereas it exhibits much lower activity against STAT3-deficient A4 cells^[1].
Crispene E (100 μM; 24 h) downregulates the mRNA expression of STAT3 and its target genes bcl-2, cyclin D1 and fascin in STAT3-dependent MDA-MB-231 breast cancer cells^[1].
Crispene E (5 μM; 24 h) selectively downregulates the protein levels of pSTAT3 and fascin in serum-starved, IL-6-treated MDA-MB-231 breast cancer cells, with no effect on pSTAT1^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

346.42

C₂₀H₂₆O₅

1666128-87-5

C[C@]12[C@@]34[C@](CC[C@@]1([H])[C@@](C)([C@H](C[C@@]2([H])OC4=O)C)CCC5=CCOC5=O)([H])O3

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Mantaj J, et al. Crispene E, a cis-clerodane diterpene inhibits STAT3 dimerization in breast cancer cells. Org Biomol Chem. 2015;13(13):3882-3886.  [Content Brief]